Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Designed to provide broad exposure to the Health Care ETFs category of the market, the iShares Biotechnology ETF (IBB) is a smart beta exchange traded fund launched on 02/05/2001.

Zacks Investment Research • Feb 25, 2026

Big Pharma Is Buying — Why Biotech Stocks Could Outperform in 2026

Biotech is quietly stepping into a leadership role here in early 2026 — and the move is not happening in a vacuum. After years of underperformance from 2021 through much of 2024, the sector began a powerful rebound in the second half of 2025.

See It Market • Feb 24, 2026

Should You Invest in the iShares Biotechnology ETF (IBB)?

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the iShares Biotechnology ETF (IBB) is a passively managed exchange traded fund launched on February 5, 2001.

Zacks Investment Research • Feb 17, 2026

Revenge Of The Dividend Stocks

Dividend stocks have sharply outperformed AI-related tech stocks since November 2025, reversing a multi-year trend. I see the rally in dividend ETFs like SCHD as overextended, prompting a pause in new purchases despite recent gains. AI is likely to benefit users more than makers, with sectors like banks, energy, and consumer staples positioned as early winners.

Seeking Alpha • Feb 7, 2026

This Wealth Manager Just Dumped Its Entire $3.5 Million Stake in the iShares Biotech ETF

Sold 24,270 shares of IBB; estimated trade value of $3.50 million based on quarterly average pricing. Net position value decreased by $3.50 million.

The Motley Fool • Jan 27, 2026

IBB: Beyond The 2025 Surge, Biotech Breakout

iShares Biotechnology ETF is rated a BUY, offering a balanced entry into biotech with large-cap stability and strong recent performance. IBB benefits from catalysts including accelerating M&A and AI-driven R&D efficiencies and more dovish Fed policy, positioning the sector for outperformance in 2026. The fund's market cap-weighted structure emphasizes cash-flow positive giants, better managing idiosyncratic risk compared to equal-weighted biotech peers.

Seeking Alpha • Jan 27, 2026

IBB: Biotech's Hot Streak May Cool

iShares Biotechnology ETF (IBB) earns a reiterated hold rating as it consolidates near all-time highs with balanced risk/reward. IBB's valuation is fair at a 19x P/E and low 3% EPS growth, resulting in an unimpressive PEG ratio. Technical momentum has slowed, with potential consolidation around $180 and long-term support near $150.

Seeking Alpha • Jan 26, 2026

Nvidia–Eli Lilly Tie-Up Shows Why AI Drug Discovery Is The Next ETF Battleground

NVIDIA Corp.'s (NASDAQ: NVDA) and Eli Lilly and Co.'s (NYSE: LLY) newly announced $1 billion AI co-innovation lab underscores how artificial intelligence is spreading beyond data centers into medicine, and ETF investors are beginning to price that into thematic funds.

Benzinga • Jan 14, 2026

Funding for Risky Biotechs Is Returning

Publicly traded drug developers sold more than $13 billion of shares in the fourth quarter, the most in more than four years.

WSJ • Jan 12, 2026

Here's Why Biotech ETFs Are Rallying Hard

Biotech rally gains steam on valuations, rate cuts, FDA wins & M&A. IBB, XBI, CANC and IDNA are ETFs near one-year highs.

Zacks Investment Research • Jan 9, 2026